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Abstract
Aim:

The aim was to study the longitudinal relationship between plantar fascia thickness (PFT) as a measure of tissue
glycation and microvascular (MV) complications in young persons with type 1 diabetes (T1DM).

Methods:

We conducted a prospective longitudinal cohort study of 152 (69 male) adolescents with T1DM who underwent
repeated MV complications assessments and ultrasound measurements of PFT from baseline (1997–2002) until
2008. Retinopathy was assessed by 7-field stereoscopic fundal photography and nephropathy by albumin
excretion rate (AER) from three timed overnight urine specimens. Longitudinal analysis was performed using
generalized estimating equations (GEE).

Results:

Median (interquartile range) age at baseline was 15.1 (13.4–16.8) years, and median follow-up was 8.3 (7.0–9.5) years,
with 4 (3–6) visits per patient. Glycemic control improved from baseline to final visit [glycated hemoglobin
(HbA1c) 8.5% to 8.0%, respectively; p = .004]. Prevalence of retinopathy increased from 20% to 51% (p < .001)
and early elevation of AER (>7.5 µg/min) increased from 26% to 29% (p = .2). A greater increase in PFT (mm/year)
was associated with retinopathy at the final assessment (ΔPFT 1st vs. 2nd–4th quartiles, χ2 = 9.87, p = .02).
In multivariate GEE, greater PFT was longitudinally associated with retinopathy [odds ratio (OR) 4.6,
95% confidence interval (CI) 2.0–10.3] and early renal dysfunction (OR 3.2, CI 1.3–8.0) after adjusting for gender,
blood pressure standard deviation scores, HbA1c, and total cholesterol.
continued
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Abstract cont.

Conclusions:

In young people with T1DM, PFT was longitudinally associated with retinopathy and early renal dysfunction,
highlighting the importance of early glycemic control and supporting the role of metabolic memory in MV
complications. Measurement of PFT by ultrasound offers a noninvasive estimate of glycemic burden and tissue
glycation.
J Diabetes Sci Technol 2012;6(2):348-355

Introduction

A

dvanced glycation end products (AGEs) are implicated
in the development of chronic diabetes complications.1
Accumulation of AGEs in long-lived proteins such as
collagen contributes to matrix expansion and decreased
elasticity in tissues, a process exaggerated in diabetes.2,3
Advanced glycation end product residues from skin
collagen homogenates are associated with the severity
of hyperglycemia and long-term microvascular (MV)
complications.4 Still, AGE heterogeneity makes their
biochemical quantification challenging, costly, and timeconsuming. Furthermore, skin biopsies are invasive and
impractical, particularly in the pediatric setting. A single
commercially available assay to adequately quantify AGEs
remains elusive.5
Assessment of the plantar fascia with ultrasound is a wellestablished method in foot care. Plantar fascia thickness
(PFT) increases with age and is greater in males than
females.6,7 Diabetes has been associated with greater
plantar fascia thickening,8 an effect likely due to collagen
glycation. The long half-life of collagen in tendons and
ligaments makes PFT, assessed by ultrasound, a relevant
surrogate measure of tissue glycation and metabolic
burden. Greater PFT has been associated with diabetic
neuropathy and decreased first metatarsal mobility in
adults.9,10 We have demonstrated that PFT measurements
at baseline predicted subsequent development of MV
complications in adolescents with type 1 diabetes (T1DM)
independent of glycated hemoglobin (HbA1c) levels,11
and a cross-sectional Egyptian study supported these
findings.12 However, the longitudinal, contemporaneous
relationship between PFT and MV complications has not
been examined.
We hypothesize that temporal trends in PFT also predict
incident diabetes MV complications, in particular that the
J Diabetes Sci Technol Vol 6, Issue 2, March 2012
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greatest increase in PFT is associated with retinopathy
and early renal dysfunction (AER >7.5 µg/min). In the
present study, we examine the longitudinal relationship
between PFT and MV complications in a cohort of
152 young adults with repeated PFT measures over a
10-year period.

Methods
This was a prospective longitudinal study of 152 (69 male)
young persons with T1DM who underwent repeated MV
complications assessments and ultrasound measurements
of PFT at the Children’s Hospital at Westmead, Sydney,
Australia. The study was approved by the Hospital’s Ethics
Committee, and written informed consent was obtained
from all participants.
Participants who attended the complications clinic between
1997 and 2002 (baseline)8,11 and had PFT measured
were eligible for inclusion in the longitudinal study.
Complications assessments and PFT measurements were
performed every 1 to 2 years from baseline during
adolescence until transition to adult care. Between 2007
and 2008, invitation letters were sent to 546 patients
who were seen at baseline for a follow-up (final) visit.
Of these, 331 could not be contacted, 34 declined, 27 agreed
but did not attend, and 2 had died. Thus, there were 152
(69 male) participants who returned for a final visit
between 2008 and 2009. Glycated hemoglobin was higher
in nonparticipants (8.9 ± 1.4% vs 8.6 ± 1.5%, p = .003)
compared with participants, but no other significant
differences in clinical characteristics were observed at
baseline. The cohort had attended a total of 698 clinical
visits from baseline to final visit [median 4 (3–6) visits
per patient].

www.journalofdst.org
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Measurement of Plantar Fascia Thickness

Plantar fascia thickness was assessed by ultrasound as
previously described.11 Briefly, participants rested prone
on an examination table with feet overhanging the edge
and toes pointing down. A linear array high-resolution
transducer was used to measure the plantar fascia.
The transducer was placed longitudinally over the center
of the arch at least 3 cm from the calcaneal insertion of the
aponeurosis. This particular site was chosen for its high
reproducibility. For each patient, seven measurements
each of the left and right PFT were performed, and
the mean PFT was calculated for each foot. The higher
of the two means (i.e., thickest fascia) was used for
analysis. All participants were free of symptoms (i.e.,
heel pain) or sonographic evidence of plantar fasciitis.
All measurements prior to the final assessment were
performed by a single examiner, using ultrasound
(ACUSON 128 gray-scale imager, Siemens, Mountain View,
CA). Final PFT measurement was performed by a second
examiner, masked to patients’ complications status, using
the LOGIQ e Compact Ultrasound (GE Medical System,
Jiangsu, China), as described earlier. In the changeover
of ultrasound machines, seven individuals had the fascia
measured (left and right foot, 14 measurements)\using
both ACUSON and LOGIQ e ultrasound machines.
The intraclass correlation coefficient between machines
was 0.98, indicating good reproducibility.
Rate of change in PFT in mm/year (ΔPFT) was estimated
by calculating the difference between final and baseline
PFTs divided by the number of years of follow-up.

Diabetes Complications Assessment

Retinopathy was detected using 7-field fundal stereoscopic
photography with a Topcon Fundus camera (TRC 50-VT,
Tokyo Optical Co., Tokyo) after dilation of the pupils
(cyclopentolate 1% and phenylephrine 2.5%). Nonsimultaneous photographic pairs taken of seven standardized fields
in each eye were viewed with a Donaldson stereo viewer.
This provides a three-dimensional representation of the
fundus and enables microaneurysms to be distinguished
from hemorrhages and artifacts. From September 2004,
the IMAGEnet 2000 Lite system was used to digitize
images. One experienced pediatric ophthalmologist graded
all photographs according to the Early Treatment Diabetic
Retinopathy Study adaptation of the modified Airlie
House classification of diabetic retinopathy, as previously
described.11 Retinopathy was defined as the presence of at
least one microaneurysm or one hemorrhage (grade 21).
Albumin excretion rate was obtained from three
consecutive timed overnight urine specimens. Although
J Diabetes Sci Technol Vol 6, Issue 2, March 2012
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microalbuminuria (MA) (AER >20 µg/min) is a wellestablished predictor of progression to overt nephropathy,
it is uncommon in young adolescents with T1DM early
in the course of disease. Lower thresholds for early
renal dysfunction (AER >7.5 µg/min) have been clearly
demonstrated as predictors of MA.13–15 We defined early
renal dysfunction as mean AER >7.5 µg/min, as this is
above the 95th percentile of normal AER described in
adolescents, and MA as AER ≥20, and <200 µg/min in
two out of three samples, as previously described.14
Glycemic control was assessed by measurement of HbA1c
using the Bio-Rad Diamat Analyzer (Bio-Rad, Hercules, CA)
from 1995 and 2001 with changeover to Variant analyzer
(Bio-Rad, Hercules, CA) for the remainder of the study
period. A cross-validation analysis found no significant
differences or systematic bias between methods in the
estimation HbA1c (R 2 = 0.99).

Clinical Measurements
Systolic blood pressure (SBP) and diastolic blood pressure
(DBP) were measured by auscultation with a conventional
mercury sphygmomanometer device, using appropriate
cuff sizes. Blood pressure was measured after 5 min of
rest in the seated position. Anthropometric data included
height measured to the nearest centimeter, weight to the
nearest 100 g, and body mass index (BMI) was calculated.
Standard deviation scores (SDS) for BMI and blood
pressure were determined using age and gender-related
reference standards.16,17
Statistical Analysis
Descriptive statistics are reported as mean ± standard
deviation (SD) for normally-distributed variables, and
median [interquartile range] for skewed distributions.
Clinical characteristics and complications rates were
compared between baseline and final visits using c2 tests
for categorical variables, including ΔPFT quartiles,
Student’s t-test for normally distributed continuous data,
and Mann-Whitney U-test for skewed data.
Longitudinal analysis of complications (retinopathy and
early renal dysfunction) was performed using generalized
estimating equations (GEE). Generalized estimating
equations extend generalized linear models to allow for
analysis of repeated measurements or other correlated
within-subject observations. Explanatory variables included
in univariate models were: PFT, diabetes duration, sex,
visit HbA1c, mean HbA1c, BMI SDS, SBP SDS, DBP SDS,
and total cholesterol (mmol/liter). We built multivariate
GEE models by incorporating variables significantly
www.journalofdst.org
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associated with complications in univariate analysis in
a stepwise fashion and examined relevant interactions.
Plantar fascia thickness and diabetes duration could not
be included in the same multivariate models due to colinearity and significant interaction terms. Adjustments
were made for total diabetes duration by including a term
of diabetes duration at the final visit (“final duration”).
For similar reasons, we adjusted for age by adding the
variable, “age at baseline.”
The variable “mean HbA1c” was created as a measure of
cumulative glycemic burden by calculating the average
of all visits’ HbA1c levels available through follow-up;
the average number of HbA1c measurements was 4.6.
Results were expressed as odds ratio (OR) and 95%
confidence interval (CI). Analyses were performed using
PASW version 18.0 (SPSS Inc, Chicago, IL).

Benitez-Aguirre

adulthood (HbA1c 8.5 ± 1.4% to 8.0 ± 1.4%, p < .001).
Females had higher cumulative mean HbA1c than males
(8.6 ± 1.2% vs 8.1 ± 0.8%, p = .01), with higher HbA1c
at baseline (8.7 ± 1.5% vs 8.3 ± 1.2%, p = .05) and final
(8.2 ± 1.6% vs 7.8 ± 1.1%, p = .08) visits. The use of
multiple daily injection therapy increased throughout the
study period (32% to 65%; p < .001), with a corresponding
decrease in total daily insulin dose per kilogram of
body weight (1.13 units/kg/day to 0.88 units/kg/day;
p < .001). Plantar fascia thickness was greater in males
than females and increased with age and diabetes duration
(baseline: 1.66 ± 0.23 mm vs 1.54 ± 0.20 mm; p = .001,
final: 1.93 ± 0.29 mm vs 1.81 ± 0.22 mm; p = .005).

Diabetes Complications
Retinopathy
During a mean follow-up of 8.3 (1.5) years, 67% (102/150)
of participants had at least one episode of retinopathy.
The point prevalence of retinopathy increased from 20% at
baseline to 51% at the final visit. There were 72 incident
retinopathy cases, of which 53 (74%) persisted at the final
visit. Participants with persistent retinopathy at the last

Results
Baseline clinical characteristics of participants (n = 152)
and nonparticipants (n = 394) are shown in Table 1.
Glycemic control improved from adolescence to

Table 1.
Baseline Characteristics for all Patients and by ΔPFT Quartiles
Nonparticipants

Participants

p

ΔPFT
Q1

ΔPFT
Q2

ΔPFT
Q3

ΔPFT
Q4

p

—

—

—

<0.010

0.010–0.035

0.036–0.056

>0.056

—

394 (49)

152 (45)

.4

36 (42)

35 (46)

37 (51)

44 (41)

.8

1.61 (0.25)

1.60 (0.22)

.7

1.76

1.61

1.54

1.49

<.001

15.0 (13.0–16.8)

15.1 (13.4–16.8)

.3

14.3

14.5

15.4

15.1

.007

6.4 (3.8–9.8)

6.6 (4.4–11.0)

.2

6.3

5.8

8.4

6.9

.4

HbA1c (%)

8.9 (1.4)

8.5 (1.4)

.003

8.3

8.7

8.5

8.5

.7

SBP (mm Hg)

117 (11)

116 (11)

.2

112 (12)

114 (11)

120 (10)

116 (11)

.018

0.63 (0.86)

0.52 (0.83)

.2

0.30

0.44

0.69

0.56

.3

69 (8)

69 (8)

.5

68 (8)

67 (7)

70 (8)

69 (9)

.3

DBP SDS

0.58 (0.76)

0.57 (0.70)

.9

0.51

0.45

0.57

0.65

.7

BMI (kg/m2)

22.9 (4.0)

22.4 (3.3)

.2

21.9 (3.2)

22.0 (2.8)

22.7 (3.8)

22.5 (3.3)

.7

BMI SDS

0.70 (0.78)

0.61 (0.69)

.3

0.61

0.62

0.51

0.61

.7

Log AER

0.71 (0.32)

0.74 (0.36)

.3

0.72

0.80

0.79

0.67

.4

ΔPFT (mm/year)
Number (% male)
PFT (mm)
Age (years)
Diabetes duration (years)

SBP SDS
DBP (mm Hg)

Retinopathy n (%)

97/377 (26)

31/145 (21)

.3

7/33 (21)

4/35 (11)

14/37 (38)

6/40 (15)

.03

AER >7.5 µg/min

83/357 (23)

35/138 (25)

.6

9/33 (27)

11/32 (34)

8/34 (24)

7/39 (18)

.5

AER >20 µg/min

19/357 (5)

9/138 (7)

.6

0/33

3/33

3/34

3/39

.4

MA

13/356 (4)

7/137 (5)

.5

0/32

3/32

1/34

3/39

.3

Q, quartile.
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Renal Dysfunction

visit had greater rate of increase in PFT (ΔPFT 1st vs
2nd–4th quartiles, c2 = 9.87, p = .02) (Figure 1).

The prevalence of early renal dysfunction (defined as
AER >7.5 µg/min) increased slightly but not statistically
significantly from 26% (38/149) at baseline to 29% (44/131)
at the final visit (p = .2). At least one episode of early renal
dysfunction was observed in 80/150 (58%) of participants
during follow-up. Of those with AER >7.5 µg/min at baseline, 15/38 (40%) met the definition of MA during follow-up
compared with 5% (6/111) of those with AER ≤7.5 µg/min
at baseline (p < .001). Microalbuminuria was observed
in 21/150 (14%) participants during follow-up, yielding a
cumulative prevalence of 10% and 16% at 10 and 15 years
of diabetes duration, respectively.

Longitudinal Analysis
There were 698 clinical visits with a median of 4 (3–6)
visits per patient available for longitudinal analysis. In
univariate GEE analysis, retinopathy was associated
with greater PFT, longer diabetes duration, female sex,
higher cumulative HbA1c (with lower ambient HbA1c),
and greater BMI SDS (Table 2). Plantar fascia thickness
predicted retinopathy, both incident and at any other
time point, after adjusting for age at diagnosis, mean
HbA1c, sex, and final diabetes duration (Table 2).

Figure 1. Frequency of retinopathy and early renal dysfunction
(AER > 7.5 μg/min) at the final visit by ΔPFT quartiles. Retinopathy
persisting at the final visit was significantly more frequent in those
above the 1st ΔPFT quartile (χ2 = 9.87, p = .02). Renal dysfunction
followed a similar trend but did not reach significance (χ2 = 2.4,
p = .05). The error bars represent 95% CI.

In univariate analysis, early renal dysfunction was
associated with greater PFT, mean HbA1c, lower BMI SDS,
and DBP SDS. These statistically significant associations
persisted in multivariate analysis (Table 3).

Table 2.
Generalized Estimating Equation Models for Retinopathy
Univariate models

Multivariate models

p

Any retinopathy
n = 150
OR (95% CI)

p

Incident retinopathy
n = 120
OR (95% CI)

p

Any retinopathy
n = 150
OR (95% CI)

p

5.36 (2.04–14.12)

.001

5.33 (2.50-11.38)

<.0001

5.3 (2.1–13.0)

.005

4.6 (2.–10.3)

<.001

2.0 (1.2–3.3)

.004

1.3 (0.8–2.2)

.2

2.0 (1.2–3.4)

.008

—

—

Age at final visit (years)

1.16 (1.07–1.26)

<.001

1.20 (1.11–1.29)

<.001

—

—

—

—

Final duration (years)

1.15 (1.08–1.24)

<.001

1.21 (1.15–1.27)

<.001

1.14 (1.07–1.22)

<.001

1.21 (1.14–1.27)

<.001

HbA1c (%)

0.72 (0.57–0.90)

.004

0.81 (0.70–0.94)

.007

—

—

—

—

Mean HbA1c (%)

1.39 (1.19–1.63)

<.001

1.35 (1.07–1.69)

.005

1.52 (1.24–1.88)

<.001

1.4 (1.2–1.7)

<.001

Total cholesterol
(mmol/liter)

1.2 (0.9–1.5)

.2

1.20 (0.97–1.49)

.09

—

—

—

—

BMI SDS

1.37 (0.97–1.94)

.07

1.49 (1.09–2.03)

.01

—

—

1.42 (1.04–1.94)

.03

SBP SDS

1.10 (0.88–1.37)

.4

1.09 (0.92–1.29)

.3

—

—

—

—

DBP SDS

1.11 (0.85–1.44)

.5

1.14 (0.93–1.40)

.2

—

—

—

—

Multiple daily injections

1.87 (1.17–2.99)

.009

1.71 (1.18-2.49)

.005

—

—

—

—

PFT (mm)
Sex (female)

Incident retinopathy
n = 120
OR (95% CI)
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Table 3.
Generalized Estimating Equation Models for Early Renal Dysfunction (AER >7.5 µg/min)
Univariate models
p

Any renal
dysfunction
n = 150
OR (95% CI)

p

Incident renal
dysfunction
n = 111
OR (95% CI)

p

Any renal
dysfunction
n = 150
OR (95% CI)

p

6.5 (2.3–18.1)

<.001

2.73 (1.17–6.35)

.02

4.9 (1.6–15.2)

.02

3.22 (1.29–8.01)

.02

Sex (female)

1.03 (0.55–1.92)

.9

0.85 (0.51–1.41)

.5

—

—

—

—

Age at final visit (years)

1.00 (0.92–1.09)

1.0

0.72 (0.95–1.07)

.7

—

—

—

—

Final duration (years)

1.06 (0.98–1.14)

.9

1.04 (0.98–1.10)

.2

1.09 (1.00–1.19)

.02

--

--

HbA1c (%)

1.26 (1.00–1.59)

.052

1.21 (1.05–1.40)

.009

—

—

1.21 (1.05–1.40)

.01

Mean HbA1c (%)

1.48 (1.02–2.14)

.04

1.27 (0.96–1.67)

.1

1.51 (1.11–2.06)

.008

—

—

Total cholesterol
(mmol/liter)

0.86 (0.59–1.25)

.4

0.87 (0.63–1.19)

.4

—

—

—

—

BMI SDS

0.95 (0.55–1.67)

.9

0.69 (0.49–0.97)

.03

—

—

0.70 (0.49–1.00)

.05

SBP SDS

0.70 (0.54–0.93)

.01

0.83 (0.69–0.99)

.04

—

—

—

—

DBP SDS

0.77 (0.58–1.01)

.07

0.78 (0.64–0.94)

.01

0.60 (0.40–0.91)

.02

0.77 (0.62–0.94)

0.01

Multiple daily injections

0.34 (0.18-0.64)

.001

0.55 (0.39-0.78)

0.001

—

—

—

—

PFT (mm)

Incident renal
dysfunction
n = 111
OR (95% CI)

Multivariate models

Discussion

In longitudinal analysis, mean HbA1c, a surrogate marker
of chronic glycemic exposure, was positively associated
with retinopathy, whereas HbA1c at each individual
visit had an inverse association. Although the inverse
association appears a paradox, we speculate this may be
explained by the significant improvement in glycemic
control from baseline to final visits. Further, mean HbA1c,
but not “visit HbA1c,” was a significant predictor of incident
renal dysfunction in both univariate and multivariate
GEE models.

In this prospective longitudinal study of 152 adolescents
and young adults with T1DM, both PFT and rate of increase
in PFT (mm/year) were associated with the development
of MV complications during 10 years of follow-up.
Despite a significant improvement in glycemic control from
puberty to early adulthood, retinopathy prevalence
increased more than twofold (20% to 51%, p < .001)
throughout the study period. These findings support
metabolic memory for retinopathy, as observed in the
Diabetes Control and Complications Trial (DCCT),18 and
underscore the importance and difficulties in maintaining
tight glycemic control during early puberty and the period
of growth and development.19 There was a nonsignificant
increase in prevalence of renal dysfunction between
baseline and final visits in keeping with the apparent
disparity observed between prevalence of retinopathy
and nephropathy. However, renal anatomical changes can
occur in the absence of renal functional abnormalities in
patients with T1DM.20

We also analyzed HbA1c SD as a surrogate marker of
glycemic variability (results not shown), and unlike other
studies,6 we found no association between HbA1c SD
and complications. Although this is likely due to the
small numbers in the present study, it suggests that PFT
may better reflect the additive effect of early glycemic
control and glycoxidative stress from glycemic variability.

Longitudinal GEE analysis demonstrated that retinopathy
was associated with greater PFT, higher mean HbA1c,
female gender, longer diabetes duration, and greater BMI
SDS. Early renal dysfunction (AER >7.5 µg/min) was
associated with greater PFT, higher mean HbA1c, longer
diabetes duration, lower BMI SDS, and DBP SDS.
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Changes in plantar fascia collagen are likely to reflect
widespread systemic glycation and AGE formation, which
may parallel changes in the vasculature. The compounding
effects of chronic hyperglycemia,21 glycemic variability,6
and oxidative stress associated with T1DM are not
comprehensively quantified by single assay measures
such as HbA1c. Abnormal glycation of proteins, lipids,
and other moieties, resulting in delayed clearance and
exaggerated accumulation of AGEs, may be better
assessed through tissue biopsy measures, as used in the
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DCCT study.4 The impractical nature of these, however,
emphasizes the role of PFT as a useful, noninvasive
measure of chronic glycation and metabolic burden,
especially in those with early vascular complications.
Our longitudinal PFT findings are in agreement with skin
biopsy AGE levels in the DCCT and their predictive
value for MV complications.4 In adults with type 2
diabetes, skin autofluorescence predicted nephropathy
but did not predict retinopathy.22 However, skin autofluorescence only detects fluorescent products, whereas
PFT is a physical measure to which both fluorescent and
nonfluorescent AGEs may contribute. A distinct advantage
of PFT is that it uses readily available, easily reproducible,
and noninvasive technology in the clinical setting.
The significant reduction in HbA1c with a parallel increase
rather than decrease in PFT suggests that early glycation
and formation of AGEs may irreversibly change collagen
structure, reflecting the differences in half-lives of
hemoglobin and skin collagen. Furthermore, these findings
are consistent with “the shape of the metabolic memory
of HbA1c” proposed by Lind and colleagues,18 who
demonstrated that HbA1c values from 5–10 years earlier
contribute the greatest risk to progression of present
retinopathy rather than concurrent visit HbA1c. The
enduring effects of glycation on collagen, both in tendons
and the microvasculature, have been demonstrated in
animal models.2,23 The role of the AGE receptor (RAGE),
through the activation of nuclear factor-kB in oxidative
stress and its association with diabetes complications,
has been explored.24 Daily glycemic variability may play
a significant role in oxidative stress, both acutely and
longer-term, which may further increase AGE production.25
The production of AGEs, activation of RAGE, and
irreversible cellular changes appear to perpetuate the
cycle of oxidative stress and further production of AGEs
independent of HbA1c.26,27
We speculate that glycemic variability, along with metabolic
memory (which may be AGE- or epigenetic-mediated, or
both), may be an explanation for the role of PFT as an
independent predictor of complications.

Benitez-Aguirre

duration, respectively. This contrasts with the findings
from the population-based Oxford Regional Prospective
Study (ORPS), which reported a cumulative prevalence
of 26% and 51% of MA after 10 and 19 years duration,
respectively.28 However, participants from the ORPS had
higher HbA1c and longer diabetes duration than our cohort.
Our cohort was clinic-based, and participants had lower
HbA1c than nonparticipants, thus selection bias may also
contribute to the differences between the two studies.
On the other hand, this selection bias towards patients
with better glycemic control supports the robustness of
PFT as a potential predictor of MV complications, since
an association was found even in those with presumably
lower levels of tissue glycation. Ideally, direct tissue
evidence of glycation and AGE levels from plantar fascia
biopsies would be available for correlation with PFT,
however, this was not feasible.
The strengths of this study include the prospective
longitudinal study design, repeated PFT measures, and
the use of all available data points using GEE modeling.
Other studies of PFT were cross-sectional in design or
used a single baseline PFT measure as a predictor of
MV complications; here we present repeated measures
in the same individual over time. Another strength of
this study is the use of the same laboratory throughout
the study to quantify HbA1c, total cholesterol, and AER.
Study weaknesses include the loss to follow-up, which
usually related to discharge from pediatric clinical care.
Study results may be influenced by the changes in
ultrasound equipment and operator for the final assessment;
however, these were validated and had a very reliable
interobserver correlation coefficient.
In conclusion, PFT is longitudinally associated with the
development of early MV complications in young people
with T1DM. These findings support the concept of
metabolic memory. Studies correlating PFT with other
noninvasive measures of tissue glycation, such as skin
autofluorescence and vascular function, will provide
further insight into the pathophysiology and clinical
relevance of tissue glycation in diabetes complications.

Our data support the cutoff value of AER >7.5 mg/min as
a measure of early renal dysfunction and an early risk
marker for subsequent development of MA.13–15 Young
people with early renal dysfunction (AER >7.5 mg/min)
at baseline were more likely to progress to an episode of
MA (40% vs 5%, p < .001) throughout the study period.
The cumulative prevalence of MA throughout the study
period was 10% and 17% at 10 and 15 years diabetes
J Diabetes Sci Technol Vol 6, Issue 2, March 2012
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